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INTRODUCTION 
This issue of the 1\1/CV Q11ar1er/_1· is devoted 
to the 48th Annual McGuire Lecture Series held 
on February 12-13. 1977. The lectures. presented 
this year by the Depart111ent of Continuing Educa­
tion. were designed to focus upon the ever-increasing 
amount of new information being generated in the 
lie Id of i 111munology. 
The progra111 title. "J111munology Update.'· is 
indicative of our attempt to provide a co111pre­
hensive view of the latest research lindings and 
developments and their implications for the clinical 
setting. Topics addressed included: (a) an overvie\\' 
of basic immunology: (b) a discussion of the clini­
cal manifestations and management of immuno­
logical disorders: (c) presentations on ho\\' to do 
ollice work-ups of immunological problems: and 
(d) discussions on the use of immunological diag­
nostic techniques. 
We wen; fortunate to have as our McGuire 
Lecturer. Richard Hong. M.D .. Professor of Pedi­
atrics. University of Wisconsin School of Medicine. 
Madison. Wisconsin. Dr. Hong is recogniled inter­
nationally ;1s one of the outstanding authorities on 
immunology. Nine other highly capable physicians 
comprised an outstanding faculty. We are in their 
debt for providing a series of lectures that proved 
attractive lo physicians. as was reflected by the 
large attendance. and one that \\'as stimulating and 
infor111;1tive. 
D/\VJD B. WALTHALL. JR .. M.D. 
Assis1w11 /)<'all for C11111i1111i11g Meli1ca/ Lt!11c111io11 
The Emerging Clinical Usefulness of 
Complement Measurements* 
SHAUN RUDDY. M.D. 
Professor of Medicine and Microbiology, and Chairman. Division of Immunology and Connective Tissue Diseases. 
Medical College of Virginia, Health Sciences Division o
f 
Virginia Commonwealth University, Richmond, Virginia 
Not many years ago the main purpose of "com­
plement" seemed to be to drill holes in sheep eryth­
rocytes. In the classic experiment which was part of 
every medical student's microbiology laboratory ex­
perience, a magic stuff called complement, somewhat 
mysteriously obtained from guinea pigs. was either 
"fixed" or not "fixed" and the sheep cells either not 
lysed or lysed accordingly.'That was about all there 
was to know about complement, and all one needed 
to know. 
Today the term "complement" embodies a 
group of plasma proteins which react in a complex 
sequence to mediate a variety of inflammatory ef­
fects, including changes in vascular permeability, the 
attraction of polymorphonuclear or mononuclear 
leukocytes, the enhancement of phagocytosis. and 
damage to cell membranes and osmotic lysis such as 
the sheep erythrocyte suffered in the complement fix­
ation test. These complement proteins rival the in­
trinsic coagulation scheme in complexity and re­
semble it in mechanism, that is. the complement 
proteins normally circulate in the plasma in an in­
active or precursor form, and when appropriately 
stimulated, usually during an immunologic reaction, 
become transformed into active enzymes, or pro­
teases. These proteases act upon their natural sub­
strates (other members of the complement system) in 
an orderly and predetermined sequence of limited 
• This work was supported by NIH grants Al 13049 and AM 
18976. and an Arthritis Clinical Research Center Grant from the 
Arthritis Foundation. New York. This is publication no. 111 from 
the Charles W. Thomas Arthritis Fund. Medical College of Vir­
ginia. 
Correspondence and reprint requests to Dr. Shaun Ruddy. 
Box 263. Medical College of Virginia. Richmond. Virginia 23298. 
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proteolytic reactions which are often compared to a 
"cascade" or "waterfall." Cleavage of one com­
ponent leads to the activation of the next component, 
and so forth. Natural inhibitors or inactivators also 
present in plasma serve to modulate or damp this 
cascade system and prevent its getting out of control. 
In fact, congenital deficiency of one of these inhib­
itors, the Cl Inhibitor, leads to uncontrolled activa­
tion of the system and recurrent swelling of the sub­
epithelial tissues of the skin, respiratory and 
gastrointestinal tracts.2 
Biochemical Pathways.•-• 
Two pathways for activation. the classic and 
alternative (properdin ), initiate the terminal attack 
sequence which elaborates most of the biologic activi­
ties associated with complement. The classic pathway 
is activated by immune complexes containing IgG or 
lgM immunoglobulins and their associated antigens. 
The properdin pathway is activated by certain kinds 
of repeating polysaccharides such as pneumococcal 
polysaccharide, or the bacterial lipopolysaccharide of 
gram-negative endotoxin: immune complexes con­
taining lgA may also activate the properdin system. 
Regardless of which pathway is activated, both 
result in the cleavage of C3 and CS. Peptides released 
from these components, C3a and CSa, are anaphy­
latoxins capable of releasing histamine from mast 
cells and thereby influencing local vascular per­
meability. CSa also releases lysosomal enzymes and 
presumably other granular contents from poly­
morphonuclear leukocytes. Both C3a and CSa have 
chemotactic activity as well, the latter being more 
active in most systems: the trimolecular complex 
formed from CS, C6, and C7 is also chemotactic. 
Immune complexes to which complement, especially 
45 
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C3b, has become bound adhere to poly­
morphonuclear neutrophils, mononuclear cells and 
B-lymphocytes. Although the functional significance 
of these binding phenomena is not yet entirely clear, 
enhanced phagocytosis by mononuclear or poly­
morphonuclear cells is certainly one consequence. 
Formation of a multimolecular complex involving 
CS, C6, C7, C8, and C9 leads to the membrane dam­
age and osmotic lysis which have become the hall­
marks of complement activation. 
Metabolism of Complement Proteins. 
One result of the proteolysis of the complement 
proteins during their activation is that they sub­
sequently become recognizable as "altered" or "for­
eign" by the body and are rapidly cleared from the 
circulation. Although some compensatory increases 
in synthesis may occur, the result is usually a fall in 
plasma level. Thus, an ongoing immunologic event 
( or disease) which is activating the complement sys­
tem in vivo may be manifested as a fall in the serum 
or plasma level of one or more of the complement 
proteins. In reverse fashion, as the complement-acti­
vating stimulus or disease abates, this may be paral­
leled by a return towards normal in the complement 
levels. 
Determinations of Complement in the Clinical Pa­
thology Laboratory. 
In principle, there are two ways of measuring 
complement: (I) by its activity in the reaction it ca­
talyzes, for example, the total hemolytic complement 
or CHSO, which measures the result of the interaction 
of all nine of the classic complement components or 
(2) by its antigenicity, as a protein in an immunoas­
say which takes advantage of the complement pro­
tein's capacity to react with monospecific antibody 
directed against it. In practice, although total he­
molytic complement or CHSO determinations are 
available in some institutions, immunoassays (usually 
radial immunodiffusion) are most frequently avail­
able. Materials for these are offered in the form of 
kits for use in the clinical pathology laboratory by a 
number of commercial suppliers. 
A few comments are in order about the radial 
immunodiffusion determinations for complement 
components available in most hospitals. 
I) Radial immunodiffusion, by its very nature, 
is not nearly as precise a determination as 
most physicians have come to expect from 
clinical laboratories. Under the best condi­
tions, the coefficient of variation of the tesl. is 
likely to be 8% or greater, more than twice 
that of commonly available clinical chemistry 
or hematologic procedures. Thus in inter­
preting the results of the test, the physician 
must take into account this reduced preci­
sion, for example, a "fall" in C3 level from 
I 45 to I 30 mg/ I 00 ml from one day to the 
next may reflect only laboratory variation. 
2) There are no widely available standards, so 
that considerable variation in absolute values 
obtained by kits from different suppliers or 
even in lots of kits from the same supplier 
may be observed. This should not be a prob­
lem if results are referred to a normal range 
collected at the institution in which the test is 
being performed, and if appropriate internal 
standards, maintained at the institution, are 
assayed in parallel with the test samples. If 
the "normal ranges" provided with the kits 
are accepted as verbatim, and if independent 
checks of the performance of the kits are 
neglected, then unreliable data may result. 
3) As for other plasma proteins, the range of 
normal for complement proteins is quite 
broad, usually in the vicinity of± 50% of the 
mean value for the population. Thus changes 
in levels in a single patient over a period of 
time may often be more helpful and easier to 
interpret than are comparisons with some ab­
solute range of normal. For example. a pa­
tient with suspect systemic lupus erythema­
tosus whose C4 level fell from 70 mg/ I 00 ml 
to 30 mg/JOO ml within two weeks might be 
cause for alarm, even though the latter value 
was still "within the range of normal." 
4) The most widely available test for a com­
plement component (C3) is not necessarily 
the most desirable. Its availability is directly 
related to the fact that C3 is by far the most 
plentiful of the complement components. the 
easiest to purify. and therefore the easiest to 
make antibody against for use in a radio­
immunoassay. Measurements of C3 were 
therefore widely available from commercial 
sources several years in advance of measure­
ments of other components. Most workers 
would agree today, however, that measure­
ments of C4 are likely to be more sensitive to 
minor episodes of in vivo complement activa­
tion. and that a good "routine" complement 
screen would include measurements of C4, 
C3, and possibly CHSO. 
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5) The immunoassays do not distinguish be­
tween native protein and that which has par­
ticipated in complement activation and lost 
its activity but not its immunogenicity. They 
are reliable, therefore, only in instances in 
which substantial amounts of cleaved, in­
active protein would not be expected. Altered 
complement proteins are cleared within a few 
hours from the plasma space, and the finding 
of altered inactive protein in plasma requires 
special techniques to detect the small 
amounts which are present. In contrast, how­
ever, altered inactive protein may persist for 
much longer times in joint spaces or pleural 
spaces, so that radial immunodiffusion deter­
minations of C3 or C4 in synovial or pleural 
fluid are of very little value. Recent studies 
have shown that measurements of C4 in cere­
brospinal fluid are similarly of little diagnos­
tic value with respect to the presence or ab­
sence of central nervous system involvement 
in systemic lupus erythematosus. 
Clinical Significance. 
Given the knowledge that the complement sys­
tem may be activated in vivo by immunologic dis­
eases, and that simple and reliable methods for mea­
suring complement levels are now widely available, 
how can the practitioner best use this information? 
What are the diseases in which complement measure­
ments are likely to be of help, either in diagnosis or in 
following the course of the patient? The answer is 
simple: any disease in which the physician suspects 
that circulating immune complexes may be playing a 
pathogenetic role. A few of them are listed in the Table. 
Systemic lupus erythematosus is the disease 
which is perhaps most commonly associated with 
hypocomplementemia, but it is well to bear in mind 
that other diseases in which circulating antigen-an-
TABLE 
Diseases in which Complement Determinations May Provide Useful 
Diagnostic or Therapeutic Information 
Systemic lupus erythematosus 
Rheumatoid arthritis (with systemic vasculitis) 
Hypersensitivity angiitis 
Angioedema 
G lomerulonephritis 
Subacute bacterial endocarditis 
Hepatitis 
Essential mixed cryoglobulinemia 
ti body complexes may be found may also give rise to 
hypocomplementemia. Among these would be in­
cluded any cause of "chronic antigenemia," for ex­
ample, subacute bacterial endocarditis, hepatitis B 
surface antigenemia, infected atrioventricular shunts, 
recurrent gram-negative sepsis, recurrent viremias 
such as dengue hemorrhagic fever, or recurrent para­
sitemia, such as falciparum malaria. Other diseases of 
unknown etiology may be associated with hypo­
complementemia, such as essential mixed cryoglo­
bulinemia, or certain kinds of nephritis (which in 
contrast to all the diseases mentioned above which 
are likely to have low C4, and sometimes low C3, 
usually have only low C3, suggesting direct alterna­
tive pathway activation). The symptom of "angioed­
ema" is infrequently associated with hypocomple­
mentemia, but a screening test should be done for C4, 
which is low in almost all cases of hereditary angioed­
ema. especially since very effective treatment for this 
disease is now available. 
In most instances in which hypocomplemen­
temia is found in association with the disease, im­
provements in complement levels are often early and 
reliable indices that the disease is ameliorating either 
spontaneously or as a result of therapy. 
Thus, by applying his understanding of "com­
plement fixation," obtained in the classical micro­
biology laboratory experiment, to human diseases in 
which "complement fixation" appears to be occur­
ring in vivo, today's physician has achieved a useful 
diagnostic tool and therapeutic index in the measure­
ment of complement components in disease. 
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Immunology and Diseases of Connective 
Tissue* 
ROBERT IRBY, M.D. 
Professor of Medicine, Division of Immunology and Connective Tissue Diseases. Medical College of Virginia, 
Health Sciences Division of Virginia Co111111onwealth University, Richmond. Virginia 
Since immune responses play a major role in the 
development or connective tissue diseases, it is not 
surprising that a number of laboratory studies reflect 
these responses. Prior to the 1940s when rheumatoid 
and LE factors became widely known, one relied 
mainly on erythrocyte sedimentation rate and serum 
electrophoresis to identify protein abnormality. Ele­
vated sedimentation rate depends on rouleaux forma­
tion, and rouleaux formation is dependent upon large 
asymmetric molecules of fibrinogen and gamma 
globulin in plasma. The demonstration of gamma 
globulin has become the cornerstone of the immuno­
logist's edifice. It is amazing to see how the sub­
specialty or immunology has mushroomed to involve 
the many facets of disease processes such as con­
nective tissue diseases, skin diseases, gastrointestinal 
diseases, renal diseases, and cancer. More recently, 
immune deficiency diseases have included the pe­
diatrician in the ever-enlarging field of immunology 
as has the modern-day discovery of human leukocyte 
antigen (H L-A) testing and tissue typing included the 
geneticist. 
In this paper, I will discuss four connective tissue 
diseases-rheumatoid arthritis, ankylosing spondy­
litis, systemic lupus erythematosus, and mixed con­
nective tissue disease syndrome-and the role immu­
nological processes play in their pathogenesis. I will 
also comment upon certain laboratory tests that use 
immunological methods in making a diagnosis. 
• This is publication No. 110 f"rorn the Charles W. Thomas 
Arthritis Fund. Medical College or Virginia. 
Correspondence and reprint requests to Dr. Robert Irby, Di­
vision of Immunology and Connective Tissue Diseases, Box 788. 
Medical College of Virginia. Richmond, Virginia 23298. 
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I. Rheumatoid Arthritis. 
It is believed that an immune process plays a role 
in the perpetuation of rheumatoid arthritis and there 
are at least five items which may provide evidence for 
this hypothesis. 
I. Lymphoid cell infiltration of the synovial 
membrane with follicle formation. Note sim­
ilarity to architecture of lymph node (Figs IA 
and IB). 
2. Local synthesis of IgG and rheumatoid factor 
by plasma cells in the synovium as demon­
strated by Smiley et al.' 
3. Decreased synovial fluid complement in some 
cases. and in other cases decreased serum 
complement as demonstrated by Ruddy and 
Schur.'·3 
4. Presence of lgG and IgM and complement 
components in the synovial lining cells and in 
remote sites of tissue damage indicating that 
some immunological process is taking place 
also at distant sites.' 
5. Presence of rheumatoid factor components 
and complement in leukocytes of synovial 
fluid cells.' 
The current concept is that IgG is produced in 
rheumatoid synovial membrane by an unknown stim­
ulus: this in turn stimulates production of lgM by 
plasma cells of the synovium and lymph nodes. Why 
IgG. which is a product of the human system, should 
serve as an antigen for IgM antibody production. is 
unknown: however. immune events may depend 
upon circulating complexes which may or may not be 
important in pathogenesis. There are some who feel 
that rheumatoid factor plays a protective role similar 
to the antistreptolysin titer in streptococcal infection, 
MCV QUARTERLY 13(2):48-56. 1977 
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Fig IA-Microscopic view (medium power) of synovial mem­
brane showing "nesting" of lymphocytes in perivascular area of 
synovium. 
while others feel that in certain systems it plays a part 
in the inflammatory mechanism. The basic pathology 
in these diseases seems to be vasculitis; hence the term 
collagen-vascular disease arose, which is a misnomer, 
since collagen is not the only connective tissue in­
volved. In rheumatoid arthritis with high rheumatoid 
factor titers and many subcutaneous nodules, one is 
more likely to see those with severe disease: pe­
ripheral neuritis, vasculitis, and leg and fingertip ulce­
rations. In these patients one may find evidence of 
antigen-antibody complement complex deposition in 
the vessels leading to the ulcers and in the perineural 
vessels of the peripheral nerves (Figs 2A, 28 and Figs 
3A, 38). 
There are a number of immunological tests 
available to make a diagnosis of rheumatoid arthritis. 
The three currently in use at the Medical College of 
Virginia are the slide latex test, sensitized human cell 
test (SHC), and the sensitized sheep cell test (SSC). 
The latex test is the most sensitive and the sheep cell 
test is the most specific for the presence of rheuma­
toid factor. Sometimes there are false-positive latex 
tests in older patients and in patients with large 
amounts of gamma globulin present. The SSC may 
be positive in low titers and in other connective tissue 
diseases. In general, all three tests employ the same 
principle. The particle, whether it be latex, human red 
cells, or sheep cells, is coated with lgG from one 
source or another, which will agglutinate in the pres­
ence of rheumatoid factor. If the sheep cell test is 
positive in a significant titer, the chances are over 90% 
that the patient has rheumatoid arthritis. It should be 
remembered that a large number of patients do not 
show rheumatoid factor, and these patients are classi­
fied as seronegative rheumatoid arthritis patients (Fig 
4 and Fig 5). 
We can identify rheumatoid factor in serum, 
demonstrate that it is produced by plasma cells in the 
synovium, and can state that in certain cases of rheu­
matoid arthritis it plays a pathogenetic role. 
Fig JB-View (lower power) showing follicle formation within 
the synovium. Note similarity lo microscopic picture of lymph 
node. This is thought to be the site of rheumatoid factor syn­
thesis. 
50 
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Fig 2A-lndolent leg ulcer in a 64-year-old male with rheuma­
toid arthritis which ultimately required below-the-knee amputa­
tion. 
II. Ankylosing Spondylitis. 
We generally categorize this as a separate disease 
entity from rheumatoid arthritis, although it has 
many similarities to that disease. There are, however, 
five specific differences: 
I. Sex and age of onset-more common in 
young males. 
2. Spine and girdle joints involved as opposed to 
peripheral joints, although peripheral joints 
may be involved in ankylosing spondylitis. 
3. Pathology is that of ankylosis, rather than 
bone destruction as seen in peripheral arthri­
tis. 
4. Absence of rheumatoid factor. 
5. Presence of a high incidence of H L-A B-27 
antigen. 
Fig 28-Area or vasculitis (medium power) in the center of a 
nerve trunk or the lower extremity. Note perivascular changes 
in the nutrient artery of the trunk. 
Fig )A-Digital vasculitis in a patient with rheumatoid ar­
thritis with gangrenous changes. 
HL-A stands for Human Leukocyte Antigen, 
and B-27 refers to its genetic locus on the chromo­
some. All of this is an outgrowth of tissue typing 
necessary in renal transplantation. We have known 
for some time that ankylosing spondylitis patients 
have a tendency to familial clustering, and there has 
been a low incidence of spondylitis in American and 
African blacks. In 1949, Toone reported studies from 
the McGuire Veteran's Hospital indicating the pau­
city of blacks who suffered from ankylosing spondy­
litis.6 Baum later confirmed this in a larger group of 
patients from a Veteran's cooperative study (Table 
I).' Schlosstein et al, and Brewerton et al, had found 
that there was a high correlation between the pres­
ence of H L-A B-27 antigen in ankylosing spondy­
litis-as high as 88% to 96%-and normal (8% in a 
controlled Caucasian population) (Table 2 ).8· 9 There 
Fig 38-Vasculitis and perivasculitis (medium power) of the 
nccrot121ng vanety showmg obhterat1on <ii the artery of the 
foot. 
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lgG 75 Antigen 
(Products of Self) 
Rheumatoid Factor Formation 
lgM 195 
Auto-Antibody 
22 S 
RF Complex 
Fig 4-Rheumatoid factor formation. Rheumatoid factors are 
antibodies which react with other immunoglobulins to form a 
rheumatoid factor complex in serum. 7S refers to sedimentation 
constant in the ultracentrifugation analysis (Svedberg units). 
are other diseases which have 8-27 as a genetic 
marker. These include Reiter's syndrome, acute ante­
rior uveitis, psoriasis with spondylitis, and others. 
To better understand the immunological pro­
cesses in developing a test such as the lymphocyte 
microcytotoxicity test (LMCT), it is important to 
understand the mechanics of the HL-A testing pro­
cedure. The LMCT is performed approximately as 
demonstrated in Figure 6. 
I. Specific HL-A 8-27 antiserum from multi­
parous women, or from those who have un­
dergone numerous transfusions as a source of 
developing 8-27 antibodies, is used. 
2. The patient's lymphocytes to be tested for 8-
27 antigen are prepared and mixed with the 
antisera and rabbit complement in the cham­
ber wells. 
Test For Rheumatoid Factor 
Negative Positive 
Fig 5-Test "ror rheumatoid factor. Rheumatoid factor complex 
will a$glutinate either latex particles, human RBC or sheep RBC 
when sensitized with IgG. In the square at lower right the 
well of.the left shows a negative test and on the right a positive 
test wioft latex irarticles. 
3. The addition of trypan blue dye will stain the 
interior of lymphocytes which have been 
lysed by the antigen-antibody complement re­
action. These lymphocytes are then counted 
under inverted phase microscopy to deter­
mine if the number of lysed cells is sufficient 
to make a specific identification of 8-27 an­
tigen. 
One may conclude then that the HL-A 8-27 
antigen is a genetic marker for the development of 
certain diseases in which spondylitis seems to be a 
common denominator. However, the part this 
marker plays in the pathogenesis of the disease is 
unknown. 
Ill. Systemic Lupus Erythematosus (SLE). 
There is no other connective tissue disease which 
has evoked more interest among immunologists than 
lupus; it might be labeled "the immunologist's de­
light." The ability to diagnose this disease stemmed 
from the Hargraves' LE cell test in 1948 through 
various patterns of antinuclear antibody (ANA) test­
ing, through the LE band test, and through the 
"lumpy-bumpy" deposits in the glomeruli. 
If one understands the basic concept of produc­
tion of experimental serum sickness, which was so 
well demonstrated by Dr. Frank Dixon with the for­
mation of immune complexes, one might understand 
more clearly the pathogenesis of such diseases as 
glomerulonephritis, rheumatic fever, SLE, and per­
haps even rheumatoid arthritis (Fig 7 ). '0 The parallel 
between these findings in experimental serum sick­
ness and human SLE and the occurrence of a wide 
range of autoantibodies against nuclear and tissue 
antigens, provides strong support for an immunolo­
gical process in SLE. These antibodies include anti­
DNA antibodies, anti-DNA histone antibodies, anti­
ribonucleoprotein (RNP) antibodies, anti-Smith 
(Sm) antibodies, and a host of others. The demon­
stration of DNA and anti-DNA antibodies in the 
TABLE I 
Racial Aspects of Ankylosing Spondylitis• 
I. Random study McGuire VA Hospital: 26 white. 3 black.­
Toone 1949 
2. Combined VA Hospital study, 301 patients: 10% black.-
Baum 1971 
3. HL-A 27 absent in Black Africans. 
4. HL-A 27 only 4% in Black Americans. 
5. HL-A 27 present in 8 of IO Black American spondylitics. 
*The above figures demonstrate the relationship of HL-A 
27 and ankylosing spondylitis on Black Americans. 
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TABLE 2 
HL-A 27 in Rheumatic Disease Patients• 
Condition Presence of H L-A 27 Percentage Source 
Normal 
Rheumatoid arthritis 
Gout 
Ankylosing spondylitis 
Reiter's syndrome 
Acute anterior uveitis 
Psoriasis 
Psoriasis/spon d yl iti s 
119/1456 
10/119 
6/66 
35/40 
72/75 
25/33 
26/50 
9/156 
6/44 
10/14 
8% Russell. 1972 
Brewerton. 197 3 
Schlosstein. 1973 
White. 1972 
8% Schlosstein. 1973 
9% Schlosstein. 1973 
88% Schlosstein. 1973 
96% Brewerton. 197 3 
76% Brewerton. 197 3 
52% Brewerton. 1973 
6% White, 1972 
14% Russell. 1972 
71% Metzger. 1974 
• A compilation of rheumatic diseases and H L-A 27 shows its strong association with ankylosing spondylitis. Reiter's 
syndrome. and psoriatic spondylitis. 
8-27 ASSAY 
#I #2 #3 
Undiluted 
0 0 0 B-27 ontisero 
Diluted 
0 0 0 B-27 ontisero 
+ 
Lymphocytes to be tested 
+ 
Trypon Blue 
( Positive test) ( Negative test) 
Fig 6-Lymphocyte microcytotoxicity test for B-27 antigen. 
Lymphocytes to be tested for B-27 antigen are added to each 
of three donor wells of diluted and undiluted specific B-27 anti­
sera. With addition of complement and t rypan blue dye, cells 
will lyse and stain positively with blue dye if B-27 antigen is 
present. 
human kidney in SLE reinforces the concept that 
SLE i, an example of an immune-complex deposition 
disease involving autoantibodies.11•12 
Prior to the widespread use of antinuclear an­
tibody testing for the diagnosis of SLE, one relied 
primarily on the demonstration of hematoxylin bod­
ies in fixed tissue, or the presence of LE cells in the 
serum. Hematoxylin bodies are globular masses of 
nuclear material which stain blue with hematoxylin 
and eosin (H & E) stain and are histochemically 
identical with the inclusion body of an LE cell. Severe 
vasculitis is the hallmark of SLE, and fibrinoid de­
posits in vessels have been shown to be composed 
chiefly of DNA, anti-DNA, and complement com­
ponents. The use of various immunological tests to 
determine the presence of ANA have taken the place 
of the LE cell test in making the diagnosis of SLE. 
The method used here is the indirect immunofluores­
cent antibody test, which employs mouse liver cells as 
the source of nuclear antigen. If antinuclear anti­
bodies are present, various patterns of immunofluo­
rescence will appear, depending on what type of an­
tinuclear antibody is present in the patient's serum. 
The patient's serum to be tested is added to the 
mouse liver cells and will adhere to the nuclear an­
tigen even when washed. When anti-human gamma 
globulin, which is commercially prepared and stained 
with fluorescin is added, a bright apple-green fluores­
cence will appear in the preparation when viewed 
under ultraviolet light (Fig 8). We have come to 
recognize four different fluorescent staining patterns, 
which may help in differentiating different patterns of 
disease expression in lupus. These include the homo­
geneous or diffuse pattern, indicating antibodies to 
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Fig 7-Circulating BSA-anti-BSA complexes: development of 
lesions. Correlation between formation of immune complexes 
with bovine serum albumin and appearance of lesions of heart. 
joints. and kidneys of rabbits with experimental serum sickness 
induced by injection of tagged BSA. 
single- or double-stranded DNA: the peripheral or 
ring pattern, usually indicating the presence of anti­
bodies to double-stranded DNA with active lupus 
present, usually with renal involvement: the nucleolar 
pattern, in which the nucleoli of the mouse liver cells 
take the stain, can be found in patients with systemic 
sclerosis or Sjogren's syndrome; and the speckled 
pattern, which stains for ribonucleoprotein and has a 
fibrillar appearance in the nucleus and is found in 
mixed connective tissue disease syndrome. It should 
be emphasized that these staining patterns and the 
statements regarding them are generalizations and 
should not be interpreted as explicit evidence in these 
cases. Sometimes we see a mixture of patterns, which 
may confuse the issue (Fig 9). 
In some cases of SLE, where a drug such as 
hydralazine or procainamide is suspected in produc­
ing the LE phenomenon and antinuclear antibodies, 
a hemagglutination test or agar gel precipitation test 
using single- or double-stranded DNA may be used. 
Antibodies to single-stranded DNA are usually pres­
ent in drug-induced SLE, whereas antibodies to 
double-stranded DNA may indicate active lupus with 
renal involvement. The A NA test is superior to the 
LE cell test in making a diagnosis in SLE because 
only 75% to 90% of patients with active SLE will have 
positive LE cell tests. Almost all patients with lupus 
will have a positive ANA test. 
The conclusion here is that SLE is the immunol-
ogist's disease-many types of autoantibodies are 
present, which can be demonstrated by various im­
munodiffusion and immunofluorescent techniques. 
These autoantibodies are thought to play a specific 
role in the pathogenesis of SLE, particularly where 
there is renal involvement. 
IV. Mixed Connective Tissue Disease (MCTD). 
The introduction of the term speckled pattern of 
A NA immunofluorescence and the presence of ri­
bonucleoprotein and Smith antigens opens the door 
to mixed connective tissue disease syndrome. 
The clinical picture of MCTD reveals it as a 
syndrome consisting of many of the features of the 
connective tissue disorders including rheumatoid ar­
thritis with arthritis and arthralgias and rheumatoid 
factor. SLE with skin rashes and speckled pattern of 
antinuclear antibody immunofluorescence, progres­
sive systemic sclerosis with Raynaud's phenomenon 
and thickening of the skin. and polymyositis with 
A 
Patient's 
Serum 
8 
Fluoresce in 
Anti yG 
Fig 8-lndirecl immunoOuorescent staining for antinuclear anti­
bodies. Mouse liver cells are used as the substrate for source of 
nuclear antigen. The r,atien1s· serum (A) containing antinuclear 
antibodies binds to the nuclei leaving a coating. After washing. 
the preparation is incubated with an anti-human gamma globulin 
(8) which hinds only al the site where antinuclear antibody is 
bound. Nuclei exposed to SLE serum will fluoresce when ex­
amined under the Ouorescence microscope. 
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NUCLEAR PATTERNS OF ANA 
ANTIGEN STAINING PATTERN 
CLINICAL CORRELATION 
Histone Component 
Deoxyribonucleoprotein 
DNA 
RNA 
R ibonucleoprotein 
RNP 
Homogenous 
or 
Diffuse 
Peripheral 
or 
Ring 
Nucleolar 
Speckled 
SLE 
RA 
OTHERS 
Active Lupus usually 
with nephritis 
SCLERODERMA 
SJOGREN'S 
SLE 
MCTD 
Fig 9- Different patterns of ANA testing. Antigen, pattern of fluorescent staining, and clinical correlation in the four types of nuclear 
antibody tests. 
myopathy and muscle enzyme changes. In other 
words, it is a "mishmash" of the connective tissue 
diseases, but generally patients are thought to have a 
better prognosis with this syndrome and as a rule do 
not have severe renal or central nervous system 
(CNS) involvement as those with systemic lupus. 
Concerning the diagnosis of MCTD, Gordon 
Sharp at the University of Missouri, who has done 
much work in this disease, feels that a diagnosis can 
be made if the clinical picture fits and one can demon­
strate antibodies to extractable nuclear antigen 
(ENA) which are RNAse sensitive. 13 Extractable nu­
clear antigen is prepared from calf thymus cells con­
taining mainly RNP and Sm antigens. This test is 
performed either by an immunodiffusion technique 
or by hemagglutination method, to demonstrate anti-
bodies to RNP and Sm antigens. RNP can then be 
removed from either test system by the addition of 
RN Ase, leaving only Sm antigen if it is present. If a 
precipitin band remains in the immunodiffusion dish 
after RNAse is added, this is Sm antigen antibody 
band, which may be present in SLE and may indicate 
a poorer prognosis than in those patients with 
MCTD (Fig 10). The hemagglutination test for RNP 
and Sm antigen is very similar to the technique em­
ployed in the tanned sheep cell test in rheumatoid 
factor. ENA is added to tanned sheep cells to coal the 
cells with RNP and Sm antigens. When the patient's 
serum containing antibodies to ENA is added, agglu­
tination results, indicating a positive test. If after 
RNAse is added there is no agglutination and the 
sheep cells fall lo the bottom of the tube, this in-
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ENA Test 
8 8 RN As� 
§ 8 
Before RNAse After RNAse 
Fig 10-Extractable nuclear antigen test (ENA): Precipitating Antibodies to RNP and Sm Antigens. ENA (RNP and Sm antigens) 
in center well of agar gel before RNAse show precipitin bands with both MCTD and SLE sera. After RNAse is added lo center well 
in figure on right bands for MCTD, sera are no longer present, leaving only Sm precipitin bands for SLE sera. 
HEMAGGLUTINATION TEST 
FOR RNP AND Sm ANTIGENS 
Fig 11-Hemagglutination test for RN P and Sm Antigens. Row I 
represents a positive ENA agglutination in a titer over 100,000 
for MCTD: Row 2 demonstrates the effect after RNAse has 
been added, identifying an RNAse-sensitive antibody, and the 
red cells fall to the bottom of the well, concluding that this 
serum contains RNP antibodies found in MCTD: Rows 3 and 
4 are sera from a normal individual with negative ENA tests 
before and after RNAse: Rows 5 and 6 represent SLE sera 
which contain antibodies to ENA which are RNAse-resistant, 
indicating no RNP to be present and Sm antigen accuunling 
for the persistent agglutination. Control sera are in the column 
on the right. 
dicates that only RNP antibodies for MCTD are 
present. If on the other hand the agglutination re­
mains after RNAse is added, this would indicate 
other antibodies, such as those to Sm antigen, are 
present, as is seen in SLE. Titers over I: I 0,000 are 
thought to be significant in the interpretation of this 
test (Fig 11 ). 
For a diagnosis of mixed connective tissue dis­
ease, high titers of hemagglutination antibodies to 
ENA and no antibodies to ENA after RNAse is 
added are required. A speckled pattern on fluorescent 
A NA test is another indication for the diagnosis. 
In a group of 100 patients studied by Sharp et al, 
74% had RN Ase-sensitive ENA by hemagglutination 
or immunodiffusion techniques, and had mixed con­
nective tissue disease. 13 Of the 26% who were RN Ase­
resistant ENA patients, a large majority had SLE. 
This group then was composed of those patients in 
whom the immunodiffusion and hemagglutination 
tests showed the presence of antibodies to Sm an­
tigen. 
One can conclude, therefore, that those patients 
who demonstrated antibodies to ENA, which are 
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R Ase-sensitive (RNP antibody), may have MCTD 
and are less likely to have renal and CNS in­
volvement and have a better prognosis. 
Summary. 
I. Rheumatoid factor can be identified in the 
sera of certain patients with rheumatoid ar­
thritis, is produced in synovial cells. and may 
have a role in pathogenesis in so111e patients. 
2. H L-A B-27 antigen is a genetic marker for 
development of certain diseases in which 
spondylitis is a common denominator: its role 
in pathogenesis is unknown. 
3. Systemic lupus erythematosus is an example 
of antigen-antibody complement complex 
deposi.tion disease. DifTerenl types of antinu­
clear-antibody tests are associated with differ­
ent patterns of disease expression. 
4. Patients with antibody lo the ribonucleopro­
lein component of extractable nuclear antigen 
may have mixed connective tissue disease and 
are less likely lo have severe renal and CNS 
involvement. 
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The Polymorphonuclear Neutrophilic 
Phagocyte 
GERALD L. MANDELL. M.D. 
Professor of Medicine. and Head. Division of Infectious Disease. Department of Medicine. University of Virginia 
School of Medicine. Char/011esvi//e, Virginia 
Patients who have too few functioning mature 
polymorphonuclear neutrophils frequently develop 
fatal bacterial or fungal infections despite our best 
efforts to prevent and treat those infections. Recently 
new facets of white cell function which enable us to 
better understand both normal and abnormal states 
have been found. Several review articles about poly­
morphonuclear neutrophils (also called neutrophils 
and granulocytes-the latter term includes eosino­
phils and basophils) have been published recently'-' 
and the reader is referred to these for more compre­
hensive coverage of the field. 
Development and Deployment of Neutrophils. 
Cells that have the potential to develop into the 
polymorphonuclear neutrophil series or into the 
monocyte-macrophage series are present in bone 
marrow. Those destined to be neutrophils go through 
a sequence of maturation steps lasting about two 
weeks. The early developing cells have a very rigid 
cell surface, are poorly motile, and cannot effectively 
engulf foreign particles. As they develop, gran­
ulocytes become progressively more flexible. more 
able to ingest foreign particles, and more efficient at 
phagocytosis and killing microbes. 
Mature polymorphonuclear neutrophils are con­
stantly released from the marrow into the circulation. 
Their half-life in the blood is about six to eight hours. 
After leaving the blood, polymorphonuclear neutro­
phils migrate to the tissues where they may live for 
several days before being destroyed. Neutrophils are 
Correspondence and reprint requests to Dr. Gerald L. Man­
dell. Division of Infectious Disease. Department of Medicine, Uni­
versity of Virginia School of Medicine, Charlollesville, Virginia 
22903. 
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destroyed by fixed mononuclear phagocytes in such 
organs as the liver. spleen, lungs. and bone marrow. 
and others are excreted in the fecal stream. Hundreds 
of millions of granulocytes enter the bloodstream 
from the marrow and leave the bloodstream for the 
tissues each day. but only a small percentage of the 
body's total number of granulocytes circulates in the 
blood at any one time. This circulating pool contains 
between 3% to 5% of the total granulocyte popu­
lation. The vast majority of mature neutrophils are 
extravascular in tissues. or waiting to be released 
from the bone marrow. It is this latter pool that is the 
source of most of the increased numbers of circulat­
ing white cells in patients with acute bacterial in­
fection. There appear to be separate regulators of 
neutrophil proliferation. maturation. and release into 
the circulation. 
Morphology and Motility. 
The mature neutrophil is about 12 to 15 microns 
in diameter and contains a multilobed nucleus. The 
characteristic of the cell reponsible for the name 
"granulocyte" is the presence of multiple granules 
containing enzymes and preenzymes in the cy­
toplasm. Other organelles are less conspicuous and 
very little in the way of ribosomal structure or mito­
chondria can be seen. There is a large amount of 
cytoplasmic glycogen which can be utilized as an 
energy source. Both microtubules and microfilaments 
can be seen in the cell in special preparations. 
Neutrophils are actively motile when in contact 
with a solid surface: they crawl rather than swim. 
Motile polymorphonuclear neutrophils look very dif­
ferent from cells seen on a stained blood smear. They 
usually have a broad front with a thin edge of cy­
toplasm (the lamellipodia) followed by a slowly ta-
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pering. roughly triangular-shaped body and a knob­
like tail. Granules are not seen in the leading edge. 
but granules do move in the cytoplasm of the cell 
where they seem to travel in roughly-defined chan­
nels. There is evidence to support the concept that 
microtubules and microfilaments are responsible for 
cell movement. 
Phagocytosis. 
After mature neutrophils leave the bone marrow 
and enter the circulation. their mission is to leave the 
vascular system and migrate to areas where they are 
needed such as an area of infection or injury. In the 
first step in this process. called margination. neutro­
phils circulating through capillaries near the site of 
injury become sticky and adhere to endothelial cells 
lining small blood vessels. Anti-inflammatory drugs 
such as aspirin and prednisone inhibit granulocyte 
adherence. The phagocytes leave the blood vessels by 
crawling through the junction between endothelial 
cells. The neutrophils are then directed towards the 
site of microbial invasion by chemotaxis. a process in 
which factors from the region of microbial invasion 
attract neutrophils towards the greatest concentra­
tion of these factors. 
After neutrophils have migrated to tissue in­
vaded by microbes. they attempt to ingest susceptible 
microorganisms and destroy them. The first step is 
recognition of the microorganisms as foreign to the 
phagocyte and a target for phagocytosis. With some 
organisms high titers of specific antibody are required 
for this recognition while in others the so-called "nat­
ural antibody" or low level of antibody usually pres­
ent in normal serum is enough to stimulate phagocy­
tosis. The antibody itself may promote phagocytosis. 
but usually the combination of antibody plus com­
plement factors is optimum for promoting phagocy­
tosis. Only immunoglobulins of the IgG class are 
opsonic. 
When a neutrophil engulfs a microbe. the lead­
ing edge of the Jamellipodia makes initial contact 
(Figure) and pseudopods are sent out. cupping the 
microorganism. This cup closes by means of mem­
brane fusion which results in the microorganism 
being enclosed in a membrane-bound space. This 
space. called the phagosome. is bounded by the ex­
ternal cell membrane which becomes internalized in 
the process. The energy for phagocytosis and loco­
motion is derived largely through anaerobic gly­
colysis. and cells are able to move and engulf organ­
isms in an anaerobic atmosphere. 
4 
Figure-A series of phase contrast photomicrographs of a human 
polymorphonu(lear ncutrophil ingesting two clumps of Srrepto­
coccu., pyogenes (L,riginal magnification. X 1200). Photomicro­
graph h, James Sulli,an and Gerald Mandell. 
Leukocyte Bactericidal Activity. 
During and after phagocytosis. granules in the 
cytoplasm move towards phagosomes which contain 
ingested particles. The contents of the granules are 
extruded into the phagosome as the granule mem­
brane fuses with the phagosome membrane. The 
phagosome. now containing lysosomal and other en­
zymes from the granules. is called the phagolyso­
some. Degranulation enables these potent enzymes to 
contact ingested microbes in the phagosome without 
exposing the cytoplasm of the neutrophil to the pos­
sible deleterious effects of the enzymes. Granules 
"disappear" from the cell during this reaction. hence 
the term degranulation. 
Along with the events described above. changes 
occur in the metabolism of the neutrophil. the most 
dramatic of which is a marked stimulation of oxygen 
consumption. The products of this oxygen consump­
tion are oxidized forms of oxygen such as superoxide 
anion (0 2 ) and hydrogen peroxide (H20,). both of 
which possess antibacterial activities. The antibacte­
rial activity of hydrogen peroxide is markedly en­
hanced by the presence of myeloperoxidase and a 
halide. In the phagolysosome containing the ingested 
microbe one finds myeloperoxidase. hydrogen per­
oxide. and a halide. which in concert can kill the 
microorganisms. Bacterial death may be the result of 
a reaction which culminates in oxidation or haloge-
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nation, or both, or vital structures on the bacterial 
surface. 
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Immunology and Diseases of the Kidney 
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The emphasis of this paper is the review of sev­
eral aspects of renal disease which have immunologic 
overtones and clinical relevance. The pathogenesis of 
several subtypes of glomerulonephritis will be dis­
cussed, the immunologic implications of amyloidosis 
will be noted, and the relation between immune 
mechanisms and tubulointerstitial disease will be men­
tioned. The discussion will then be completed by an 
analysis of the prognosis of the aforementioned renal 
diseases, and by an attempt to place contemporary 
therapeutic modalities in a proper perspective. 
Before treating each of these subjects, it is worth 
acknowledging the important contribution which 
evaluation of renal biopsy tissue has made to our 
understanding of the relation between immune mech­
anisms and renal disease. The availability of fresh 
tissue from biopsies in living patients has allowed 
adequate evaluation by immunoAuorescent micro­
scopy and electron microscopy (EM). Each of these 
techniques has provided important and com­
plementary information about the nature of fine 
structural damage induced by immune mechanisms.' 
Immune Complex Disease. 
Pro/ifera1ive G/omerulonephriris. 
Figure I is an immunoAuorescent stain for lgG 
in the glomerulus of a patient with acute post­
streptococcal glomerulonephritis. A Auorescin­
tagged antibody against lgG has been layered over a 
quick-frozen biopsy specimen and become attached 
to the lgG. The positive Auorescent lumps are 
thought to represent deposits of antigen-antibody 
Correspondence and reprint requests to Dr. William F. Falls. 
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complexes adjacent to the capillary basement mem­
branes and in the mesangium (the supporting stalk) 
of the glomerulus. It is assumed that these histologic 
abnormalities reAect the following series of path­
ogenic events: an antigenic derivative of the strepto­
coccus has entered the circulation: an antibody re­
sponse has developed: soluble immune complexes 
have been formed in a state of antigen excess: the 
complexes have precipitated in the glomerulus: com­
plement components have been fixed: and the com­
plement cascade activated with resultant production 
of inAammation and damage to the gomerulus. Un­
der certain circumstances immunoAuorescent stains 
may identify complexes containing lgM and lgA as 
well as various components of the complement sys­
tem and fibrinogen.' 
Figure 2 is a light microscopic view of a glomer­
u l us from another patient with acute post­
streptococcal glomerulonephritis. This picture is the 
light microscopic correlate of the immunoAuorescent 
preparation described above. The features of a dif­
fuse proliferative glomerulonephritis including swell­
ing of the tufts. a marked increase in cellularity (pri­
marily mesangial cells). occlusion of the capillary 
loops. and an inAux of polymorphonuclear leu­
kocytes are present. It is likely that the leukocytes 
have been attracted by leukotactic factors released by 
activation of the complement cascade.' 
Figure 3 is an EM preparation showing part of 
the ultrastructure of a glomerulus from the biopsy of 
a patient with poststreptococcal glomerulonephritis. 
The pathologic findings include fusion of the foot 
processes of the epithelial cells and deposition of 
large. electron-dense deposits adjacent to the sub­
endothelial surface of the basement membrane. It is 
thought that these deposits represent the immune 
complexes which have been discussed above. Post-
MCV QU/\RTERL Y 13(2): 60-68. 1977 
FALLS: IMMUNOLOGY AND DISEASES OF THE KIDNEY 61 
Fig 1-lmmunofluorescent microscopic preparation (anti-lgG) or 
a portion or a glomerulus from a patient with poststreptococcal 
glomerulonephritis. Note the "lump-bumpy" pattern. (X 1500). 
streptococcal glomerulonephritis is characteristically 
associated with large "humplike" deposits in the sub­
epithelial position, but this finding is not absolutely 
diagnostic because a similar locus of depositon has 
been noted in other immune-complex-mediated renal 
diseases such as syphilis with nephritis.' 
Subsequently, it will become evident that im­
mune complexes may localize on either side of the 
basement membrane. The reason a deposit may lo­
cate in a given site (either subepithelial, sub­
endothelial, or intramembranous) is not entirely de­
fined. Current theory holds that the location of 
immune-complex deposits may depend upon their 
physical characteristics, with smaller deposits 
Fig 2-Light microscopic preparation (H & E) or a portion or a 
renal biopsy from a patient with diffuse prolirerative glomerulo­
nephritis following a streptococcal inrection (X 200). 
Fig )-Electron microscopic preparation or a portion or a glome­
rulus from a patient with acute poststreptococcal glomeruloneph­
ritis. Note the large subepithelial electron-dense deposit. "hump" 
( X 32.000). 
(formed by combination of antigen with low affinity 
antibody) localizing in a subepithelial site and large 
complexes localizing subendothelially.' There is also 
evidence to suggest that complement-binding sites 
may be present in the region of the epithelial cell foot 
processes.' Complexes which have fixed complement 
prior to traversing the basement membrane may be 
snared by attachment of complement with these re­
ceptors. 
Figure 4 is the light microscopic view of two 
glomeruli from a patient with a staphylococcal albus 
Fig 4-Light microscopic preparation (H & E} or a portion or a 
renal biopsy rrom a patient with "shunt nephritis" secondary to 
staphylococcal inrection. Note that glomerulus in the center and 
the portion or the glomerulus at the lower margin both show 
prolirerative changes ( x 200). 
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Fig 5-Electron microscopic preparation of a portion of a glome­
rulus from a patient with systemic lupus erythematosus and a 
diffuse proliferative lesion by light microscopy. Note the large 
subendothelial deposits (X 10.000). 
infection of a ventriculojugular shunt which had been 
made because of hydrocephalus. The lesion is a dif­
fuse proliferative glomerulonephritis and could not 
be distinguished from the poststreptococcal lesion by 
conventional light microscopic or immunofluores­
cent studies. Figure 5 is an EM study showing a large 
subendothelial deposit from a patient with lupus er­
ythematosus and proliferative glomerulonephritis by 
light microscopy. The subendothelial region is the 
favored site of deposition in lupus. 1 Figure 6 shows 
the light microscopic appearance of a glomerulus 
from a patient with focal proliferative glomerulo­
nephritis. Note that segments of the glomerular tuft 
Fig 6-Light microscopic preparation (H & E) of a portion of a 
renal biopsy from a patient with systemic lupus erythematosus 
showing a focal proliferative lesion (X 400). 
appear to have normal cellularity and that the in­
flammatory reaction is less severe than in the cases 
noted earlier. lmmunofluorescent and electron mi­
croscopic studies would show the immune deposits to 
be less numerous and to have more of a mesangial 
location than in the diffuse proliferative lesion. IgA 
deposition is seen with greater frequency in the mes­
angium in focal lesions. 1 
After a review of the first six figures it is clear 
that the classic light microscopic picture of pro­
liferative glomerulonephritis, either diffuse or focal, 
reflects a disorder of immune-complex deposition in 
the region of the glomerular capillary basement mem­
brane and mesangium. From observation of the path­
ologic material it is also easy to envision that the 
inflammatory process would lead to leakage of albu­
min, red blood cells, and immunoproteins into the 
urine with development of an "active" urine sedi­
ment. The mediators of inflammation in proliferative 
lesions are not well understood but are thought to be 
released by activation of the terminal portion of the 
complement cascade. 1 Serum levels of early-reacting 
complement components and C, are frequently, but 
not invariably, reduced in patients with immune­
complex-mediated proliferative lesions. The antigenic 
substances which may be involved in this type of 
lesion are numerous and will be discussed below. 
Membranous Glomerulonephri1is. 
Another histologic pattern of renal involvement 
that is almost certainly mediated by glomerular im­
mune-complex deposition is membranous glomerulo­
nephritis (Fig 7). Note that the only abnormality is 
marked thickening of the capillary basement mem-
Fig 7-Light microscopic preparation (PAS) of a portion of a 
glomerulus from a patient with membranous glomerulonephritis 
(X 200). 
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brane. Figure 8 demonstrates that the cause of the 
basement membrane thickening is the presence of 
numerous dense deposits along the epithelial border 
of the basement membrane with projections of base­
ment membranelike material interposed between the 
deposits. Fusion of the epithelial cell foot processes 
adds to the breadth of the capillary wall and probably 
has been induced by the marked albumin leak which 
most of these patients experience. lmmunofluores­
cent studies show a fine granular deposition of IgG 
and IgM as would be expected from the location of 
the deposits on EM.' On occasion. complement com­
ponents also may be identified in the glomerular ca­
pillaries, but this occurs with much less frequency 
and in a more scant distribution than in proliferative 
lesions. Serum complement levels are usually normal 
in membranous glomerulonephritis. The absence of 
an inflammatory response may relate to the presence 
of immune complexes which fix complement poorly, 
or to an impotent complement system. As might be 
expected, patients with the membranous lesion usu­
ally develop a nephrotic syndrome and tend to have a 
less "active" sediment than those with a proliferative 
process. 
Antigens Associated with Immune Complex Dis­
ease. 
There are a large number of disorders in which 
antigen-antibody complex deposition is recognized or 
suspected as being the cause of renal disease.' Ex­
ogenous antigens, particularly drugs and foreign pro­
teins, may induce an immune-complex glomerulo­
nephritis with the appearance of either a proliferative 
Fig 8-Electron microscopic preparation of a portion of a glome­
rulus from a patient with membranous glomerulonephritis. Note 
the numerous subepithelial deposits. ( x 15,800). 
or a membranous lesion. A number of bacterial or­
ganisms including the streptococcus, staphylococcus, 
pneumococcus, and treponema pallidum have in­
duced a complex-mediated nephritis which is usually 
proliferative in pattern. Plasmodium malariae may 
cause either a proliferative or membranous nephritis. 
It is suspected that numerous viral agents may incite 
immune-complex-mediated renal disease. Both hepa­
titis-B virus and the Barr-Epstein virus have been 
clearly identified as providing the antigenic stimulus 
for an immune-complex-mediated disorder. The for­
mer has been incriminated as inducing proliferative 
and membranous lesions as well as a generalized 
arteritis. 
Perhaps the best defined of all immune-complex­
mediated renal diseases is that associated with sys­
temic lupus erythematosus. It is clear that in this 
disorder endogenous cellular antigen (DNA, RN A, 
and numerous derivative substances) provides an in­
exhaustible source of antigen for complex formation. 
Diffuse proliferative, focal proliferative, and mem­
branous nephropathy have been identified in patients 
with systemic lupus. 
Recently, considerable excitement has been gen­
erated by the discovery of other endogenously-pro­
duced antigens which may cause renal disease in man. 
A derivative of tubular brush border has been identi­
fied as the antigenic component of an immune-com­
plex-induced membranous glomerulonephritis in pa­
tients with sickle cell anemia.' The nephrotic 
syndrome secondary to a membranous lesion has 
been recognized in some patients with solid tumors of 
the lung and colon: in a patient with the latter neo­
plasm carcinoembryonic antigen has been identified 
as part of the complex on the basement membrane.• 
Immune-complex glomerulonephritis may be seen 
with some frequency in patients with cryoglobuli­
nemia, particularly those in whom there is a mixed 
IgG-IgM cryoglobulin with rheumatoid factor activ­
ity.• 
After reviewing all of the known causes of im­
mune-complex-mediated renal disease one is left with 
an unrecognized antigen as the stimulus for the dis­
ease process in most cases of the idiopathic nephrotic 
syndrome. This includes patients with focal pro­
liferative, diffuse proliferative, or membranous le­
sions. The offending antigen is also unknown in such 
syndromes as Wegener's granulomatosis and He­
noch-Schonlein purpura. Within the next few years 
the inciting antigens will be identified in many of 
these disorders and may well prove to be viral agents. 
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Fig 9-lmmunofluorescent preparation (lgG) from a portion of a 
biopsy of a patient with anti basement membrane antibody disease. 
Note the linear pattern of fluorescence (X 1500). 
Antibasement Membrane Antibody Disease. 
Figure 9 is an immunofluorescent stain showing 
homogeneous linear deposition of IgG along the 
basement membrane of the glomerulus. This pattern 
is thought to represent the attachment of antibase­
ment membrane antibody to some antigenic com­
ponent in the basement membrane. The antibody is 
usually lgG although linear deposition of IgM and 
complement have also been described in some cases. 
In many patients, circulating antibody can be demon­
strated by allowing the patient's serum to react with 
sections of normal human kidney. The mechanism 
whereby deposition of antibasement membrane an­
tibody leads to renal damage is uncertain, but that 
severe damage can be induced is amply demonstrated 
by Figure 10 which shows a proliferative lesion of 
both the mesangial and epithelial cells. Proliferation 
of the latter with crescent formation is apparently 
induced by the leakage of large molecular weight 
fibrin precursors into Bowman's space through tears 
in the basement membrane. 1 
An occasional epithelial crescent can be found in 
virtually any type of renal disease, but involvement of 
essentially the entire glomerular population is seen in 
two circumstances: rapidly progressive glomerulo­
nephritis and Goodpasture's syndrome. Many pa­
tients with the clinical picture of idiopathic, rapidly 
progressive glomerulonephritis and most patients 
with Goodpasture's syndrome (lung hemorrhage and 
nephritis) will display evidence of antibasement 
membrane antibody as the cause of renal damage. 
The offending antibody in Goodpasture's syndrome 
cross-reacts with pulmonary basement membrane 
and is thought to induce the pulmonary as well as the 
renal disease. The stimulus for production of anti­
basement membrane antibody is uncertain, but dam­
age to pulmonary or glomerular basement membrane 
by viral agents or chemical irritants with uncovering 
of hidden antigenic sites has been suggested as a 
mechanism. 1 As might be expected, patients with an­
tibasement membrane antibody disease and crescent 
formation frequently have very "active" urine sedi­
ments and may be nephrotic. 
Glomerulonephritis and Activation of the Alter­
nate Complement Pathway ( Membranoproliferative 
Glomerulonephritis). 
In general terms. when the complement system is 
activated in the disorders discussed above. it is prob­
ably brought about by the classic pathway (C i � C, 
� C, � C,). Recently. however. evidence has begun 
to accumulate suggesting that activation of the latter 
part of the complement cascade via the so-called 
"alternate pathway" may be of importance in in­
ducing renal damage. 1 Activation of the "alternate 
pathway" has been noted in some cases of post­
streptococcal glomerulonephritis. but the most pro­
vocative evidence for a role of this pathway has been 
observed in patients with the pattern of membrano­
proliferative or mesangiosclerotic glomeruloneph­
ritis. 
West and his associates originally described a 
group of children with heavy proteinuria: "active" 
urine sediments: low circulating C, levels: light m1-
Fig 10-LighI microscopic preparation (H & E) from the renal 
biopsy of a patient with antihascmcnt membrane antibody disease. 
otc the marked crescent formation and interstitial inflammatory 
reaction (X 80). 
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croscopic evidence of cellular proliferation, increased 
mesangial matrix, and a tendency to lobulation of the 
glomerular tufts: glomerular C, deposition with little 
or no accompanying IgG or lgM by immunofluores­
cence: and a circulating activator of C, (C, nephritic 
factor).• The patients were considered to be a unique 
group and designated as having membranoprolifera­
tive glomerulonephritis with hypocomplementemia. 
Subsequently, it has been recognized that patients 
with membranoproliferative lesions are not a homo­
geneous group: and they have now been subdivided 
into two groups, primarily on the basis of EM fea­
tures. Type I patients show evidence of splitting and 
reduplication of the basement membrane and have 
electron dense deposits. The activation of early com­
plement components and the infrequent demonstra­
tion of circulating C, nephritic factor in this group 
suggest the presence of a classic immune-complex­
mediated disease. Type II patients, on the other hand, 
show a marked homogeneous increase in density of 
the glomerular capillary basement membrane with­
out evidence of deposits ( dense deposit disease).' Cir­
culating C, nephritic factor is usually present and 
early reactive complement components are normal. 
The nature of the dense transformation of the base­
ment membrane is uncertain and the pathogenesis of 
this disorder remains to be defined. 
Lipoid Nephrosis of Childhood (Nil Disease). 
Another disorder which classically has been con­
sidered with the glomerulonephritides is lipoid neph­
rosis of childhood or nil disease. This is the most 
common cause of the nephrotic syndrome in child­
hood. The only recognizable histologic abnormality 
in patients with this disturbance is fusion of the foot 
processes recognizable on EM (Fig 11 ). The etiology 
of this disorder is uncertain, but renewed interest in 
the possibility of its being an immunologic disease 
has been kindled by the discovery of a similar lesion 
in several patients with Hodgkin's disease who have 
the nephrotic syndrome. Since current thought sug­
gests that Hodgkin's disease may be a T-cell distur­
bance, it has been suggested that nil disease reflects a 
disturbance of cellular immunity.• 
Focal Segmental Sclerosis. 
A subgroup of children with the idiopathic neph­
rotic syndrome who do not respond well to the thera­
peutic agents mentioned below has been described 
recently. This group frequently has mild microscopic 
hematuria as opposed to the children with typical nil 
Fig I I-Electron microscopic preparation of a portion of a renal 
biopsy from a patient with .. nil disease.·· Note the normal appear­
ing basement membrane. the absence of deposits. and the presence 
of fused foot processes (X 14.000). 
disease who show no "activity" of the urinary sedi­
ment. Segmental sclerosis beginning in the juxtame­
dullary glomeruli and progressing to become a dif­
fuse generalized involvement with ultimate global 
sclerosis has been identified in these children. 
Amyloidosis. 
Amyloidosis of the kidney is an interesting cause 
of the nephrotic syndrome which, on clinical 
grounds, may be confused with the glomerular dis­
eases previously mentioned and which has a close 
relationship to the body's immune systems. On light 
microscopy the glomerular mesangium may appear 
infiltrated with a homogeneous material and the 
basement membrane may be thickened. Such a pat­
tern may be confused with diabetic nephropathy or a 
late stage of immune-complex-mediated nephropathy 
which has led to significant sclerosis: staining with 
Congo red and viewing the sections under polarized 
light will demonstrate the typical apple-green 
birefringence if amyloid fibrils are present. however. 
The amyloid fibril also gives a characteristic appear­
ance by EM as demonstrated in Figure 12. 
Exciting recent work has provided a clearer un­
derstanding of the nature of amyloid. The amyloid 
fibrils seen in patients with B-cell dyscrasias, either 
multiple myeloma or primary amyloidosis, are 
thought to be composed of light-chain derivatives of 
the paraprotein produced by the abnormal B cells.'0 
An entirely unique protein (AA protein) has been 
identified as composing the amyloid of patients with 
secondary amyloidosis related to chronic infection or 
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familial Mediterranean fever. 10 The reason that these 
different proteins have similar refractive properties 
and give a similar appearance on EM relates to the 
fact that they share the same beta-pleated arrange­
ment of their amino acid components. 
Tubulointerstitial Disease. 
Investigation of the immunologic aspects of 
tubulointerstitial disease has been overshadowed by 
the tidal wave of studies evaluating the mechanisms 
of immunologic glomerular damage. Interest in the 
interstitium has been rekindled, however, by the dis­
covery of an association between the ingestion of 
certain drugs and the development of interstitial 
nephritis. It is now evident that a molecular moiety of 
several members of the penicillin family may act as a 
hapten, combine with an endogenous protein to 
make a complete antigen, stimulate an antibody re­
sponse, and ultimately result in precipitation of im­
mune complexes in the region of the tubular base­
ment membranes with incitement of a diffuse 
interstitial inflammatory reaction." A utoantibodies 
to tubular basement membrane have also been dem­
onstrated and incriminated as the cause of interstitial 
infiltration in lupus erythematosus, the transplanted 
kidney, and the crescentic disease of Goodpasture's 
syndrome and rapidly progressive glomerulonephritis 
(Fig 10).' Studies in animals have suggested that 
chronic pyelonephritis may be perpetuated by cellu­
lar immune mechanisms originally activated by the 
release of antigenic substances from tissues damaged 
by invading pathogenic bacteria.' 
Prognosis and Treatment. 
Having reviewed the current thoughts about the 
pathogenesis and histologic appearance of immuno­
logically related renal disease, we ought now to at­
tempt to apply this information in a fashion that will 
be beneficial to a given patient. Such application 
is practical in two major areas, prognosis and treat­
ment. The importance of a renal biopsy in obtain­
ing tissue for evaluation is obvious. Its importance in 
obtaining practical prognostic and therapeutic infor­
mation which will help the patient is variable. For 
example, a renal biopsy is not likely to be helpful in 
the management of the patient with obvious inter­
stitial disease as manifested by leukocytes and a rela­
tively scant amount of albumin in the urine. If the 
disease is drug induced, it will probably resolve spon­
taneously with discontinuation of the offending agent. 
Fig 12-Electron microscopic preparation of a portion of a glome· 
rulus showing amyloid fibrils (X 24.000). 
It is among patients with an unexplained nephrotic 
syndrome that evaluation of an adequate renal 
biopsy is most helpful. 
Prognosis. 
Patients with focal proliferative glomerulone­
phritis. lipoid nephrosis. and membranous glome­
rulonephritis have a relatively good prognosis either 
treated or untreated. Lupus patients with a focal 
proliferative lesion may live for years without show­
ing evidence of deterioration in renal function. Many 
children with nil disease undergo a spontaneous re­
mission and when deterioration in function occurs. it 
usually progresses very slowly. Patients with drug­
related or tumor-related membranous nephropathy 
may have remission of their disease with removal of 
the offending antigen: those with an idiopathic mem­
branous lesion, or lupus and a membranous lesion. 
may spontaneously remit or remain nephrotic with 
an unchanged creatinine clearance for years.' 
On the other hand. patients with diffuse pro­
liferative lesions unrelated to a specific infecting or­
ganism, particularly those with lupus erythematosus. 
have a poor prognosis. Most patients with antibase­
ment membrane antibody disease and marked cres­
cent formation will reach the terminal stage within 
two years. 
Patients with membranoproliferative glomerulo­
nephritis tend to have an intermediate prognosis with 
most showing progressive deterioration in renal func­
tion to its terminal stage in 5 to 12 years.' Amyloid 
patients and patients with segmental sclerosis also 
demonstrate an intermediate prognosis. 
As knowledge accumulates. we may feel obliged 
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to perform a biopsy on every patient with chronic 
renal disease who is progressing toward its terminal 
stage in order to determine his or her ultimate can­
didacy as a transplant recipient. Antibasement mem­
brane antibody disease, membranoproliferative 
glomerulonephritis, and focal segmental sclerosis 
have been recognized as recurring in grafted kidneys, 
ultimately leading to their failure. Indeed, it is now 
considered inappropriate to transplant a patient with 
antibasement membrane antibody disease if circulat­
ing antibodies can be demonstrated in his or her 
serum. 1 
Treatment. 
Much has been written about the treatment of 
immunologically related renal diseases. Unfortu­
nately, except for the management of two disorders, 
nil disease and Wegener's granulomatosis, there is 
little agreement and much bias about specific treat­
ment. Diuretics are of great symptomatic value in 
edematous states but have no effect on basic path­
ogenic mechanisms. The agents which have been used 
as possible inhibitors of immune mechanisms include 
corticosteroids, antimetabolites, and alkylating 
agents. Each of these drugs has significant toxicity, 
particularly when used over a prolonged period, and 
their modes of action remain uncertain. The natural 
history of many of the immunologically related renal 
diseases is variable and capricious. Consequently, 
controlled studies, involving numerous patients and 
extending over a long period of time, are needed to 
establish the efficacy of any drug regimen. These 
studies have not been done. Outlined below is a per­
sonal assessment of the state of the art of immuno­
therapy in renal disease. 
As already mentioned there seems to be uniform 
agreement that therapy is effective in those patients 
with nil disease and those with Wegener's gran­
ulomatosis. In lipoid nephrosis the administration of 
corticosteroids will enhance the rate of remission, 
and the duration of remission after relapse can be 
prolonged by supplementing the steroids with cy­
clophosphamide or chlorambucil. Nil disease in 
Hodgkin's disease will subside with treatment of the 
lymphoma. Cyclophosphamide is effective in produc­
ing a sustained remission in the renal disease of 
Wegener's granulomatosis, a disorder which was for­
merly uniformly lethal.12 
Treatment in a patient with immune-complex­
mediated diffuse proliferative or focal glomerulo­
nephritis is most effective if it can be directed at 
eradication of a recognizable inciting antigen. Ob­
viously, this is most successful if the antigen is de­
rived from an infectious agent such as a staphylococ­
cus or a spirochete. If the antigen cannot be removed 
as in lupus erythematosus, one must carefully weigh 
the potential benefits of therapy against the possi­
bility of significant drug toxicity. It is my impression 
that most authorities would tend not to treat a focal 
proliferative lesion in lupus but would be aggressive 
in the management of a patient with a diffuse pro­
liferative lesion. In the latter case, one might use a 
combination of steroids and either azothioprine or 
cyclophosphamide in doses sufficient to return sero­
logic indicators of disease activity such as C, levels or 
anti-DNA antibody levels to normal. 13 
The management of membranous glomerulo­
nephritis of either the idiopathic type or that asso­
ciated with lupus erythematosus is equally per­
plexing. Controlled studies done in Great Britain in 
the 60s suggested that no therapy was effective in the 
idiopathic membranous lesion." However, recent un­
controlled retrospective analysis16 · 16 and an ongoing 
American cooperative study17 suggest that prolonged 
steroid administration may be helpful. 
Therapy for patients with crescentic disease has 
included steroids, azothioprine, cyclophosphamide, 
and anticoagulation agents. Isolated cases treated 
with these agents have shown good responses, but 
there have been no controlled studies to substantiate 
this fact. Steroids have been advocated as being of 
value in membranoproliferative lesions, 1• but here 
again there have been no comparisons with a com­
parable untreated population. 
There seems to be no specific treatment for am­
yloidosis. However, amyloid deposition may be in­
hibited by treatment of an underlying myelomatous 
state or by correction of a smoldering infectious proc­
ess.' Success has been reported recently in reducing 
proteinuria in amyloid disease secondary to familial 
Mediterranean fever by the administration of colchi­
cine.'0 
Summary. 
The relation between the immunologic systems 
and renal disease has been brieAy reviewed and sev­
eral pathogenic immunologic mechanisms have been 
correlated with the histologic pictures which they 
produce; this information has then been related to 
contemporary thoughts about prognosis and therapy. 
Much has been learned, but there is obviously much 
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more to be done, particularly in the areas of pre­
vention and treatmenf. 
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Cancer: The Great Challenge for Immunology 
GERALD GOLDSTEIN. M.D. 
Professor a/Medicine. Unirersi1r of Virginia School of Medicine. Charlonesville. Virginia 
The existence of immunity to cancer was postu­
lated by the eminent scientists who helped to estab­
lish the discipline of immunology. In 1907 Clowes 
suggested that human resistance to cancer resulted 
from what we. today call "immune surveillance." 1•2 
During the ensuing 70 years the results obtained from 
experimental animal cancers and human cancers have 
greatly influenced the palatability of tumor-immunity 
theories.3·' Early optimism that immunity to cancer 
could be specifically induced waned and almost dis­
appeared when it was demonstrated that the rejection 
of cancer transplants resulted from transplantation 
immunity and not tumor immunity. A sustained 
wave of enthusiasm for immunity to cancer appeared 
after demonstrations that inbred animals could be 
immunized to cancers arising in the inbred strain.5· 6 
The objective of this paper is to try to reexamine 
many aspects of cancer immunology and to shift the 
emphasis currently placed on some of these aspects 
into other areas with greater potential for clinical 
application. This is not meant to be one of the numer­
ous reviews of cancer immunology but rather a bal­
anced presentation of alternative viewpoints which 
will ultimately tilt toward my viewpoint. 
The plan for the paper is as follows: ( I ) the types 
of contributions immunology has made to mankind 
will be briefly reviewed: (2) a general theory describ­
ing cancer immunity with some supporting evidence 
will be presented not once but twice: (3) finally the 
current status of immunotherapy of human cancer 
will be briefly mentioned. 
Co111ribwions o/Im111uno/ogy. 
A review of the major contributions of immu­
nology to humanity should offer a preview of what 
can reasonably be expected from future contributions 
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of this field to the understanding and control of can­
cer. The trademark of immunology is prevention of 
disease by immunization. With the discovery of anti­
biotics and their use in tissue cultures. a fresh attack 
upon many viral infections became possible. In the 
past two decades. the cultivation of viruses in vitro 
has resulted in the elimination of epidemics of po­
liomyelitis: infection with measles virus is less com­
mon. Where the human is the sole host and reservoir 
of an infection. immunization may lead to the eradi­
cation of a disease. This appears to be the attainable 
goal in smallpox where we are at the threshold of its 
eradication by intensive immunization and epidemio­
logic field work. 
While the trademark is immunization. the work 
horse of immunology is serology. lls use in diagnosis 
and blood banking alone are of critical importance to 
the functioning of our hospit<c1ls. A strike of all tech­
nicians doing serologic tests would paralyze our 
health care system. In addition to its diagnostic con­
tributions. immunology provides an important un­
derstanding of the pathogenesis of disease. 
A relatively new but potentially major contribu­
tion is in predicting susceptibility to disease. The 
association of certain transplantation antigens with 
specific disease states may be the forerunner of sero­
logic identification of disease-risk factors. 
When one turns to the role of immunology in 
therapy. the work seems harder and the results hardly 
optimal. This view is not meant to belittle the value of 
replacement therapy in certain immune deficiency 
diseases, or of immunosuppressive therapy in pre­
venting transplant rejection: rather it is intended to 
point out that cancer immunology is much, much 
more than immunotherapy. 
Grneral Frn1ures of" /111111uni1y 10 Cancer. 
All cancer immunology is inextricably linked to 
the existence of an antigenic difference between the 
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cancer cell and its closest normal "relative'' cells. 
Without such a difference, immunology has no entry 
into the cancer field. 
The transformation of a normal cell to a cancer 
cell is probably accompanied by an antigenic change. 
This transformation may occur frequently in all of us. 
With a properly functioning immune system, the an­
tigenic change or changes in the cancer cells are rec­
ognized and following recognition an effective anti­
cancer cell immune response destroys the malignant 
cells. Appearance of clinical cancer is thus considered 
to be a prima facie case of a failure of normally 
operating immunologic mechanisms. 
Ei;idence Supporting Immune Surveillance. 
Origins for cancer antigens are not hard to find. 
Oncogenic viruses are obvious sources of extraneous 
antigenic material incorporated into cancer cells. 
While no human oncogenic virus has been clearly 
identified, several viruses are viewed with suspicion. 
Chemical compounds play an important role in the 
initiation of human cancer, and for many years these 
carcinogens included many compounds that are also 
mutagens. Recently a bacterial test for detecting 
chemical mutagens has shown that almost every 
known chemical carcinogen is either a mutagenic 
agent or is metabolized to a mutagen.' Chemical 
carcinogen-induced changes in the bases of deoxyri­
bonucleic acid (DNA) can result in the synthesis of 
abnormal. that is, antigenic, proteins. Similarly. 
physical agents such as ultraviolet and x-irradiation 
are also known carcinogens and mutagens. 
Amongst the wide variety of human cancers, an 
impressive list of cancer-associated "time and place" 
antigens have been detected.•-10 The carcinoembry­
onic antigen of the gastrointestinal tract. alpha-feto­
protein. chorionic gonadotropin, antidiuretic hor­
mone. and parathormone are examples of normal 
product made by cancers that are either abnormal 
for postnatal life or for that type of cell. 
As we move to consider the evidence for the 
existence of immune cancer-rejection systems, we 
need to rely on negative observations. It is impossible 
to demonstrate that we are cancer-free as a result of 
active recognition and destruction of small clones of 
cancer cells. but strong circumstantial evidence 
points to such immune mechanisms. Patients who are 
recipients of organ transplants have a high risk of 
subsequently developing a malignant disease11 ·12 : 
these patients are estimated to be at least 25 times 
more likely to develop cancer than the normal popu­
lation. 
GOLDSTEIN: CANCER AND IMMUNOLOGY 
An additional group of patients at high risk for 
developing cancer are those individuals with im­
munodeficiency diseases. From 5% to I 0% of patients 
with sex-linked agammaglobulinemia, combined im­
munodeficiency disease, Wiskott-Aldrich, or ataxia 
telangiectasia will develop clinical malignant disease. 
Further but less definite indications that we are pro­
tected by immune mechanisms include the observa­
tions that chemical carcinogens may be immunosup­
pressive,1• the claims of cutaneous anergy in patients 
with neoplastic disease, 1'- 1' and the frequently stated 
view that patients with cancer have an increased sus­
ceptibility to infection. 1• 
The last element to be considered in the con­
struction of an immunologic lattice for the contain­
ment of cancer is the alteration of the course of 
cancer by immunologic methods-immunotherapy. 
Attempts to stimulate a specific immune response1' 
and to stimulate the entire immune response by 
agents like bacille Calmette Guerin (BCG )'0 have 
been extensively performed. In 1971, a comprehen­
sive review was published by Yashpie,'1 and the re­
port of a conference entitled. "lmmunotherapy of 
Cancer: Present Status of Trials in Man," held in 
Washington in October, 1976, is to be published. 
How effective is immunotherapy for human can­
cer? It is important to realize that the concept of the 
"proof of the pudding is in the eating" is as much 
determined by how hungry one is as by the quality of 
the pudding. Rather than enthuse about immuno­
therapy, I prefer to accept its present meagre results 
as a challenge to reexamine our entire position. I will 
also consider immunology with respect to prevention, 
pathogenesis, early diagnosis, treatment monitoring 
aids, and immunotherapy. 
Prevention of Human Cancer by Vaccines. 
An extensive review of the possibilities in this 
area was recently published." At least two major 
obstacles need to be overcome before vaccines for 
human cancer become a reality. First and foremost 
the link between a human virus and the cancer it 
causes needs to be firmly established. Then the virus 
can be developed into a vaccine-living, killed. or 
subunit. The second problem is to determine who 
should receive the vaccine. Since the incidence of any 
one kind of carcinoma is relatively low, methods are 
needed to identify the high-risk groups. Where the 
prevalence of a carcinoma may be 5 to 10 persons per 
100,000, it would be unacceptable to try to immunize 
the whole population. 
Where a viral-associated neoplasm behaves like 
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a communicable infectious disease, a vaccine could 
be very helpful. Such a situation exists in the poultry 
industry. A DNA herpes-like virus (Marek's disease 
virus) is manufactured into a fully infectious form in 
the feather follicle of the chicken. In addition this 
virus spreads within the chicken and causes a fatal 
lymphoreticular disease; it also spreads amongst 
chickens and can wipe out a flock. An effective vac­
cine has been prepared from an apparently harmless 
herpes virus of turkeys. This vaccine protects the 
chickens against Marek's disease!• 
The Pathogenesis of Cancer. 
Immunologists searching for human cancer anti­
gens have made an astounding, although largely ig­
nored, contribution to our understanding of the 
pathogenesis of cancer. Despite years of search by 
numerous competent investigators, a cancer-specific 
antigen has not been isolated for any human cancer. 
Although the search for cancer-specific antigens is 
too important to be abandoned, the possibility that 
specific cancer antigens do not exist must be faced. 
Instead of cancer-specific antigens, cancer-associated 
antigens have been found. Some of these antigens are 
considered time antigens. A cancer cell makes fetal 
alkaline phosphatase, or a fetal pyruvate kinase 
isozyme, or embryonic antigens, or structures such as 
alpha-fetoproteins; place antigens also are made. 
Thus a variety of normal hormones are made by 
malignant cells derived from cells that have ceased 
making these products. Frequently these hormones 
produce symptoms in the patient, a paraneoplastic 
syndrome. Were we to have the full catalog of normal 
gene products made from conception to maturity, it 
is possible that a time or place antigen or both could 
be associated with every human cancer. The finding 
of time and place cancer-associated antigens instead 
of cancer-specific antigens fits in with an intriguing 
new concept of the pathogenesis of cancer;• which as 
its essential feature regards cancer as a programming 
error. Carcinogenesis is not a mutation to new struc­
tures but rather a reactivation of genetic programs 
that were terminated a long time ago. In this view 
viruses, chemicals, and physical agents act by going 
· into the "old book" section of the cell's DNA library 
and activating something long dormant. 
It is possible to estimate the percent of the infor­
mational DNA that is being actively transcribed by 
cells. There is no difference in the amount of DNA 
active in the blastula phase, the gastrula phase, or the 
adult cells. About 3% of the DNA is being used, but 
the 3% used in the gastrula phase cells is not identical 
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to the 3% used by the blastula cells. Thus normal 
development consists of the orderly and sequential 
production and elimination of portions of the DNA 
program. 
Can programs be initiated? Dr. Ruddy referred 
to androgen treatment of hereditary angioedema. 
The administration of an androgen leads to synthesis 
of a significant amount of a protein necessary to 
inhibit spontaneous activation of the complement 
system; other examples exist, perhaps the best being 
the reactivation of the information locked up within a 
cell nucleus as reported by Gurdon.2' Trans­
plantation of organelles produced striking results 
when the nucleus of a fertilized frog ovum was re­
moved and replaced by the nucleus of a mature frog 
muscle cell. The microsurgically treated cell was then 
restored to its proper environment, and development 
of the ovum resulted in the formation of a tadpole. 
All the information for this development was uncov­
ered in an orderly fashion from the mature nucleus of 
a differentiated cell. Similar results have been ob­
tained when the nucleus from a mature frog lym­
phocyte was transplanted into an enucleated ferti­
lized frog ovum. 
Our society seems to have more difficulty in for­
mulating the correct questions than it does in provid­
ing the answers to these questions. The finding of 
several cancer-associated antigens emphasizes that 
cancer immunologists must continue to examine 
serologically the early stages of development with the 
objective of identifying additional tumor-associated 
antigens that in turn may be critical in establishing 
valid early diagnostic tests for cancer. 
The Nature of the Immune Defect in Cancer. 
The failure to demonstrate an effective immuno­
therapeutic method requires that the defects in the 
immune surveillance and rejection system be exam­
ined again with respect to cancer. 
Does the patient who develops a carcinoma of 
the lung, or breast, or stomach or other organs have a 
defect that is applicable to the recognition and reac­
tion to many antigens or is the defect confined to the 
antigen or antigens associated with that particular 
cancer? This is not a trivial question since the direc­
tion for future immunotherapy depends on the an­
swer. Arguments in favor of a broad defect are the 
high incidence of neoplasm in transplant patients and 
in those with immune deficiency diseases, but the 
interpretation of this evidence is not decisive. Cy­
totoxic immunotherapy is not exclusively immuno­
suppressive. It may interfere with DNA repair mech-
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an isms which if unchecked could cause malignancy as 
seen in xeroderma pigmentosa. 26 These patients have 
a very high incidence of neoplasms of the skin, and 
severe impairment of the ability to repair the damage 
in DNA caused by ultraviolet irradiation. Many of 
the drugs used in immunosuppression may also inter­
fere with DNA repair mechanisms. 
The evidence suggesting that there is no broad 
immune defect in cancer patients is drawn from the 
incidence of infection in patients with solid neo­
plasms. Since the earliest days of immunology, in­
fection has pointed to the areas where immune de­
fects exist, and it is unusual to see clinically 
significant immune defects without concomitant fre­
quent infection. Indeed the defects may be so subtle, 
as in sickle cell disease, that increased susceptibility 
to infection is recognized long before the nature of 
the immune defect is discovered. 
Contrary to general opinion, infection is not a 
common problem in the patient with solid cancers, 
although infection certainly occurs when large masses 
obstruct a passageway or become necrotic. If exten­
sive chemotherapy renders the patient gran­
ulocytopenic, or if large doses of steroids are given, 
infection occurs, but under other circumstances, in­
fection in a non-terminal cancer patient is rare. Ac­
counts of infection in cancer patients are pre­
dominantly those of patients with leukemia, 
lymphoma, and myelorna. Of 93 patients with asper­
gillosis, only 14 had solid tumors." Of these, 11 were 
receiving steroids and nine were receiving cytotoxic 
drugs. Another recent report'" shows that 31 of 35 
patients treated for infection with sulfamethoxazole­
trimethoprirn had hematologic malignancies; so it 
goes with all reports of infection in cancer patients. 
It appears to me unlikely that the overwhelming 
majority of patients with solid tumors have a large 
blind spot in their immune system. Skin testing for 
anergy, counting T and B lymphocytes, and stimu­
lating lymphocytes with mitogens can probably be 
safely discontinued or replaced by looking for the 
real defect in the immune system in cancer patients. 
This leads to the second question. How does an 
antigenic cancer escape detection') The answer to this 
question is beset with technical difficulties. The re­
ports of two workshops29· 30 designed to evaluate the 
results of in vitro cytotoxicity tests for cancer cells are 
gloomy. More emphasis needs to be placed upon 
technical improvements in the culturing of cancer 
cells and in determining their in vitro susceptibility to 
antibody and to lymphocytes and macrophages. 
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Our understanding of this area is intimately tied 
to our efforts in human cancer immunotherapy. An 
outline of how a cancer breaks through or may break 
through is of value even though it is purely specula­
tive. Early studies in malignant melanoma" stressed 
the importance of humoral antibodies. Patients with 
localized melanoma were reported to have antibody 
which reacted with melanoma cells while patients 
with disseminated melanoma generally lacked these 
antibodies. Using in vitro techniques, the Hellstroms 
demonstrated a more complex Trojan Horse type of 
immunologic arrangement" in which lymphocytes 
from a cancer patient could destroy in vitro cancer 
cells removed from that patient. This cellular immune 
reaction could be inhibited by antibody present in the 
serum of that cancer patient and from these observa­
tions a dual immune system was formulated-an­
tibody could protect the cancer, and cellular immun­
ity could destroy the cancer. Further modifications 
have been made in both the serum and cellular as­
pects, but the basic premise remains that the destruc­
tion or growth of a cancer depends upon the relative 
strengths of two types of immune reactions. This 
point should be returned to in considering the results 
of immunotherapy. 
Immunology and Early Diagnosis of Cancer. 
Early diagnosis implies identification of the pres­
ence and location of malignant cells at a time when 
curative treatment can be performed. Today none of 
the immunologic tests for cancer-associated antigens 
are sensitive and specific enough to meet this require­
ment. 
The nature of the immunologic tests for cancer­
associated antigens is qualitatively different from 
tests measuring levels of liver enzymes or bone en­
zymes. In the latter tests, it is unlikely that a small 
mass could raise the level of normally present en­
zymes to an abnormal level; that is, there is a high 
background of normal activity that obscures the sim­
ilar activity of the neoplastic cells. In the immuno­
logic tests, the search is for fetal antigens in which the 
background levels should be low. This is an area in 
which future progress may produce valuable results. 
f 111111unologic Treatment Monitoring A ids. 
Three radioimmunoassay tests are currently of 
great value in the management of patients with can-
cer. 
The carcinoembryonic antigen (CEA) test is of 
great assistance in management of some patients with 
colorectal carcinoma. Where the level is elevated pre­
operatively, the postoperative levels are useful in as-
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sessing the recurrence of disease and the response to 
therapy. We are not recommending adjuvant post­
operative chemotherapy, but an elevation in the CEA 
is one indication to search for the location of the 
recurrence and for initiation of therapy. 
Radioimmunoassay of chorionic gonadotropins 
has long been known to be essential in planning the 
treatment of choriocarcinoma. The radio­
immunoassays for alpha-fetoprotein and for the B­
subunit of chorionic gonadotropin add a major new 
dimension to our management of patients with testic­
ular cancer. Decisions about starting chemotherapy 
and the selection of the chemotherapy drugs used are 
greatly influenced by the results of these immunologic 
tests. 
lmmunotherapy of Cancer. 
I have not allotted much space to the analysis of 
cancer immunotherapy. Many techniques-some 
simple, some complex, and some very ingenious-are 
being used to either treat human cancer or to prevent 
its recurrence. 
The experimental studies of BCG immunization 
in the guinea pig" illustrate the potential value and 
the limitations of immunotherapy. In this system, 
injection of living Mycobacterium bovis BCG into the 
tumor residing in an animal capable of developing 
cellular reactivity to BCG, and at a time when the 
tumor is small, results in a marked decrease in the 
number of tumor-transplantation takes. Many exper­
imental animal systems carefully designed to demon­
strate an effect of immunotherapy have been pub­
lished. The literature on human cancer 
immunotherapy trials is enormous; its abundance 
makes it difficult to discount. In my view the effec­
tiveness of any immunotherapeutic procedure in hu­
man cancer has yet to be demonstrated. There is great 
interest in studying the results reported at the confer­
ence "lmmunotherapy of Cancer: Present Status of 
Trials in Man." 
Predicting the future course of immunothera­
pists is hazardous. The mood or moving spirit seems 
to indicate a great disenchantment with BCG and its 
allied products. A shift to Corynebacterium parvu/um 
is underway, but it is probably too toxic to gain wide 
acceptance. The newest bacterial entry is the pseudo­
monas vaccine. The direction seems to be to go 
through Bergey's Manual, a task that could involve 
generations. 
Ironically BCG is being rejected as uncritically 
as it was accepted. If we are to be able to interpret an 
immunotherapy trial properly, we need to know 
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more than the change in size of a cancer mass or the 
duration of survival. We need measurements of the 
changes in the levels of antitumor blocking antibody, 
unblocking antibody, and cellular cytotoxicity and 
cellular suppression. With this information we can 
learn how to stimulate selectively the portion of the 
immune response that destroys cancer without stimu­
lating the immune response that aids cancer. 
Conclusions. 
Immunology provides a valuable tool as a treat­
ment monitoring aid in many cancers. 
The likelihood of an effective cancer vaccine is 
remote and requires identification of both an onco­
genic virus and a susceptible subgroup. 
The failure to find cancer antigens and the abun­
dance of cancer-associated antigens suggest that can­
cer may be a programming error and potentially re­
versible. 
Immunology is likely to provide better and effec­
tive early diagnostic tests. 
The major need in immunotherapy is laboratory 
support to measure the effects of therapy upon anti­
tumor immune response. 
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Introduction. 
We have recently seen two patients with cystic 
medial necrosis of the aorta. The first patient died of 
a dissecting aneurysm of the thoracic aorta. At au­
topsy. classical Hashimoto·s thyroiditis was discov­
ered. The second patient died of a rupture of the 
ascending aorta. At autopsy. chronic thyroiditis was 
seen with multiple large germinal centers and diffuse 
fibrosis. Neither patient was clinically suspected of 
thyroid dysfunction although the second patient had 
had a partial thyroidectomy in the remote past. 
The association of dissecting aneurysm and post­
thyroidectomy myxedema in three patients was re­
ported many years ago.' Autoimmune thyroiditis 
with symptoms of hypothyroidism and dissecting 
aneurysm have also been observed together.' It has 
also been reported that aortic aneurysm appears to be 
significantly more frequent in myxedematous patients 
than in other hospitalized patients.3 The underlying 
theme in these clinicopathological correlations ap­
pears to be that hypothyroidism may cause weak­
ening of the aortic wall. This report is meant to focus 
attention on this possibility and point out that sub­
clinical cases of hypothyroidism may also involve the 
aorta. 
Case Report I. 
A 76-year-old black woman who had a history of 
mild hypertension was brought to the emergency 
room because of sudden low back pain and "spells" 
earlier the same day. Her vital signs were a pulse of 
Corrcspon<lcn<.:c and reprint requests to Or. William S. Wi!'-c, 
Department or Pathology. Huron Road Hospital. 1.\951 Terrace 
Road. Cleveland. Ohio 44112. 
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68/min. blood pressure 120/84 mmHg. respiration 
44/min. She had prominent epigastric aortic pulsa­
tions. A chest x-ray showed cardiomegaly and a wid­
ened mediastinum probably due to the thoracic 
aorta. She had multiple PVB's on her elec­
trocardiogram. She suddenly became unresponsive 
after her physical exam and died. 
The autopsy was performed 17 hours after 
death. There was a dissecting aneurysm of the tho­
racic and abdominal aorta and a hemopericardium. 
The aorta showed mild to moderate atherosclerosis, 
but the thoracic and abdominal aorta were grossly 
pliable. Marked cystic medial necrosis was seen with 
hematoxylin and eosin staining and was confirmed by 
the significant metachromasia seen with the aldehyde 
fuchsin and toluidine blue stains. The heart weighed 
450 gm and the left ventricle was 2 cm thick. Moder­
ate atherosclerosis of the major coronary arteries was 
present and the myocardium had moderate diffuse 
interstitial fibrosis. The thyroid had a diffuse lym­
phocytic infiltrate together with germinal centers and 
Hlirthle cell change. The morphological criteria for 
Hashimoto·s thyroiditis were therefore fulfilled. 
Case Report 2. 
A 55-year-old black woman experienced the sud­
den onset of severe sharp midepigastric pain while 
ascending a flight of stairs and immediately lost con­
sciousness. She was brought to the emergency room 
in a state of shock. Arter admission the patient had 
generalized seizures followed by episodes of ventricu­
lar tachycardia and ventricular fibrillation. She re­
sponded to resuscitation at first but later developed 
cardiac arrest and died. She had no history of hyper­
tension and had been taking no medications. Ten 
MCV QU/\RTERLY 1.1(2): 76-77. 1977 
WISE AND HAIN: AORTIC NECROSIS IN HYPOTHYROJl)ISM 77 
years prior to this episode she had undergone a par­
tial thyroidectomy for thyroid nodules. 
An autopsy was performed four hours after 
death. A large rupture in the wall of the ascending 
aorta extended into the adventitia of the aorta and 
pulmonary arteries. A hemopericardium containing 
100 cc of blood and clot was present. The abdominal 
and thoracic aorta were markedly atherosclerotic. 
Marked cystic medial necrosis was seen in the ascend­
ing aorta and significant metachromasia was demon­
strated with the toluidine blue stain. The heart 
weighed 450 gm and showed left and right ventricular 
hypertrophy. The left anterior descending coronary 
artery was 50% occluded by atherosclerosis within I 
cm of the coronary ostia. Scattered areas of early 
myocardial necrosis were seen microscopically. The 
thyroid was small and firm. and one lobe had been 
previously removed. A marked chronic thyroiditis 
composed of diffuse lymphocytic infiltration. promi­
nent germinal centers. and scarring was present. but 
there was no Hlirthle cell change. The partial thyroi­
dectomy done ten years previously showed the same 
histologic pattern. A single sigmoid kidney was pres­
ent on the right as a result of crossed renal ectopia 
with fusion. 
Discussion 
The two patients in this report both had cystic 
medial necrosis of the aorta and died as a result of 
complications of the weakened aortic wall. Both pa­
tients were hypertensive based either on history or on 
the autopsy findings of cardiomegaly and left ven­
tricular hypertrophy. Systemic hypertension is often 
present in patients dying of dissecting aneurysms' 
and ruptures of the aorta. Whether the hypertension 
has a causative role in cystic medial necrosis or only 
functions to propagate a tear is not fully understood. 
Both of the patients in this report had undiag­
nosed thyroid diseases at autopsy. In the first patient 
Hashimoto's thyroiditis involved the entire gland. 
The second had had a partial thyroidectomy and the 
remaining thyroid tissue showed chronic thyroiditis. 
There was diffuse fibrosis and multiple germinal cen­
ters, but no Hlirthle cell change was seen in this 
patient and we were therefore reluctant to classify 
this as a classical Hashimoto's thyroiditis. The ana-
tomic evidence suggests that both of these patients 
could have had episodes of hypothyroidism which 
were not detected, so-called preclinical myxedema. 
The effect of total lhyroidectomy without thy­
roid hormone replacement in hypertensive patients 
has been documented by Kountz and Hempelmann.' 
Two patients died of dissecting aneurysm within six 
months. A third patient was treated with desiccated 
thyroid for two years. She slopped taking her replace­
ment hormone and ten months later died of dis­
secting aneurysm. All three patients had cystic medial 
necrosis. The findings suggest that hypothyroidism is 
a severe risk factor in the development of dissecting 
aortic aneurysm in hypertensive patients. 
More recently an association of Hashimoto's 
thyroiditis and dissecting aneurysm was reported.' 
This case involved a patient who was also hyperten­
sive and clinically hypothyroid. Thyroid auto-anti­
bodies were present. Medial degeneration was not 
documented. but severe atherosclerosis was present. 
An association of hypothyroidism and abdominal 
aneurysm has also been shown by Niarchos and 
Finn.3 They suggest that preclinical myxedema pa­
tients might be picked up with a more sensitive 
screening test. such as with antithyroid antibodies or 
serum thyroid stimulating hormone (TSH) levels. In 
addition. we suggest that patients with aortic 
aneurysm might be screened more carefully for evi­
dence of preclinical myxedema. In such patients. fur­
ther weakening of the muscle wall might possibly be 
prevented. 
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